Araceli Biosciences Secures $4.5M in Funding

Araceli Biosciences, a Tigard, Oregon-based company developing cellular imaging platforms for drug discovery, has raised $4.5 million in funding from backers including Jeff Swickard.

The company will use the investment to support its commercial growth and move into the next-phase of its business. This includes launching consumable products designed for its existing installed base, with a broader rollout planned for 2027.

What is Araceli Biosciences?

Araceli Biosciences develops cellular imaging platforms that help pharmaceutical and biotechnology companies study how human cells respond to drug compounds.

Read More:Axle Raises $9M to Expand Its AI Corporate Access Platform

Its Endeavor platform combines cellular imaging technology with AI-driven analysis software. It allows researchers to monitor cell responses and generate biological data for drug discovery, and advanced screening.

The technology supports New Approach Methodologies (NAMs), which use human cell based assays to assess drug safety and effectiveness. These methods can help researchers reduce reliance on animal testing and collect relevant data earlier in drug development.

How Much Funding Has Araceli Biosciences Raised?

Araceli Biosciences has raised $4.5 million in its latest funding round. The company has not disclosed details of previous funding rounds or it's total funding to date.

Who Invested in Araceli Biosciences?

Jeff Swickard was among the backers participating in the $4.5 million funding round. No other investors were named in the announcement.

The investment also reflects Swickards interest in supporting Oregon's technology, and life sciences sector.

Why the Funding Matters

Pharmaceutical companies are increasingly adopting technology driven approaches to drug discovery, including AI and human cell based testing methods.

Araceli's Endeavor platform supports this shift by helping researchers study cellular responses to drug compounds and generate scalable, reproducible data.

The new funding will support the company's commercial expansion, including the launch of consumable products designed for its growing installed base.

Who founded Araceli Biosciences?

Araceli Biosciences was founded in 2020 and spun out of Phoseon Technology in 2023. The company is headquartered in Tigard, Oregon, where most of its approximately 30 employees are based.

The source did not disclose the names of its founders.

"We are excited to join an impressive group of investors in Araceli Biosciences, an innovative Oregon company developing technology with the potential to modernize scientific research and reduce the need for animal testing. We believe the future of science should be smarter, faster, and more humane. That future is already taking shape in Oregon, and we're proud to be part of it," said Jeff Swickard.

Market and Business Growth

Araceli's technology is used by leading pharmaceutical and life sciences companies, including 10 of the world's top 20 pharmaceutical companies.

The company has established a presence in the San Francisco Bay Area, Boston, London and Berlin. Its customers across North America and Europe use the Endeavor platform and AI-driven software for drug discovery and screening applications.

What Happens Next?

Araceli plans to enter the next-phase of its commercialisation by launching consumable products tailored to its existing installed base.

The company is targeting a broader rollout in 2027 as it works to expand the commercial reach of its cellular imaging technology.

Read More:Kindo Raises $30M to Expand Its Enterprise AI Platform